Sarcoma Clinical Trial
Official title:
Dose Escalation of Total Marrow Irradiation Added to an Alkylator-Intense Conditioning Regimen for Patients With High Risk or Relapsed Solid Tumors
RATIONALE: A peripheral blood stem cell transplant or bone marrow transplant using stem cells
from the patient may be able to replace immune cells that were destroyed by chemotherapy and
image-guided intensity-modulated radiation therapy used to kill tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of bone marrow
radiation therapy followed by an autologous stem cell transplant in treating patients with
high-risk or relapsed solid tumors.
OBJECTIVES:
Primary
- To determine the maximum tolerated dose of tomographic total marrow irradiation (TMI)
when given prior to an alkylator-intensive conditioning regimen in patients with
high-risk or relapsed solid tumors.
Secondary
- To determine the feasibility of performing positron emission tomography (PET) scans and
spot radiation to PET-positive lesions after transplantation.
- To determine the change in bone mineral density and turnover in patients treated with an
alkylator-intensive conditioning regimen and TMI.
OUTLINE:
- Mobilization chemotherapy and peripheral blood progenitor cell (PBPC) collection:
Patients receive ifosfamide intravenously (IV) and etoposide IV on days -100 through
-30.
Beginning 24 hours after completion of chemotherapy, patients receive filgrastim (G-CSF)
subcutaneously (SC) or IV until blood counts recover. Patients then receive an increased dose
of G-CSF SC or IV once daily for 3 consecutive days. Beginning on day -97, patients undergo
up to 4 collections of PBPCs. Patients who do not yield an adequate number of cells undergo
bone marrow harvest.
- Bone marrow harvest: Patients undergo bone marrow aspirate and biopsy 2 weeks after the
last dose of G-CSF. If the aspirate or biopsy is morphologically free of tumor cells and
demonstrates > 20% cellularity, then patients receive sargramostim (GM-CSF) daily for 5
days followed by bone marrow harvest.
- Total marrow irradiation (TMI) with tomotherapy: Patients undergo escalating doses of
TMI* to all bony sites using helical tomotherapy image-guided intensity-modulated
radiotherapy on days -11 to -9.
NOTE: *Patients with primary CNS tumors do not receive TMI but are eligible to receive
chemotherapy and hematopoietic progenitor cell rescue in accordance with the protocol.
- Conditioning regimen: Patients receive busulfan IV over 2 hours four times daily on days
-8 to -6, high-dose melphalan IV over 30 minutes on days -5 to -4, and thiotepa IV over
2 hours on days -3 to -2.
- Autologous CD34+ hematopoietic progenitor cell transplantation: Patients undergo
reinfusion of autologous G-CSF-mobilized peripheral blood or bone marrow progenitor
cells on day 0. Patients also receive G-CSF support beginning on day 0 and continuing
until blood counts recover for 2 consecutive days.
- Post-transplantation radiotherapy: Patients may receive additional radiotherapy to areas
of known metastatic disease, PET-positive lesions, primary disease (if not previously
irradiated to maximum tolerated dose), and lungs beginning on day 60 post
transplantation. Patients with prior lung metastasis may receive up to 10 fractions of
whole-lung irradiation.
Patients may also receive additional radiotherapy to primary disease if maximum tolerated
dose has not yet been reached.
Patients undergo bone mineral density studies at baseline and at days 60, 120, and 180 post
transplantation. Patients also undergo blood sample collection periodically during study for
pharmacokinetic analysis of busulfan.
Patients undergo PET scans at baseline and on day 60.
After completion of study therapy, patients are followed at days 180 and 365 and then
periodically thereafter.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04457258 -
68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma
|
Early Phase 1 | |
Recruiting |
NCT04986748 -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
|
||
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Recruiting |
NCT04535713 -
GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
|
Phase 2 | |
Completed |
NCT03521531 -
Burden and Medical Care of Sarcoma in Germany
|
||
Completed |
NCT02496520 -
Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults
|
Phase 1/Phase 2 | |
Terminated |
NCT02054104 -
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
|
Phase 1/Phase 2 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04577014 -
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT04052334 -
Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
|
Phase 1 | |
Completed |
NCT01593748 -
A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma
|
Phase 2 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Recruiting |
NCT04367779 -
Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
|
||
Completed |
NCT01879085 -
Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04553692 -
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers
|
Phase 1 | |
Completed |
NCT01209598 -
PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma
|
Phase 2 | |
Completed |
NCT04553471 -
Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers
|
N/A | |
Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 |